Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Acorda Therapeutics (ACOR)

Acorda Therapeutics (ACOR)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 75,887
  • Shares Outstanding, K 48,030
  • Annual Sales, $ 471,430 K
  • Annual Income, $ 33,680 K
  • 60-Month Beta 1.18
  • Price/Sales 0.17
  • Price/Cash Flow 0.69
  • Price/Book 0.31

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.65
  • Number of Estimates 4
  • High Estimate -0.33
  • Low Estimate -1.07
  • Prior Year 0.41
  • Growth Rate Est. (year over year) -258.54%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.49 +2.01%
on 11/20/19
2.82 -46.00%
on 10/23/19
-0.94 (-38.21%)
since 10/18/19
3-Month
1.49 +2.01%
on 11/20/19
4.46 -65.92%
on 09/11/19
-1.70 (-52.80%)
since 08/20/19
52-Week
1.49 +2.01%
on 11/20/19
21.13 -92.81%
on 11/29/18
-17.04 (-91.81%)
since 11/20/18

Most Recent Stories

More News
Look for Shares of Acorda Therapeut to Potentially Rebound after Yesterday's 6.99% Sell Off

Acorda Therapeut (NASDAQ:ACOR) traded in a range yesterday that spanned from a low of $1.78 to a high of $1.91. Yesterday, the shares fell 7.0%, which took the trading range below the 3-day low of $1.86...

ACOR : 1.52 (-3.80%)
Acorda Therapeutics Announces Departure of President, International & General Counsel

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that Jane Wasman, President, International & General Counsel, is resigning from the company effective at the end of this year. Ms. Wasman plans...

ACOR : 1.52 (-3.80%)
Zoetis (ZTS) Beats on Earnings in Q3, Reports In-Line Sales

Zoetis (ZTS) beats earnings estimates, while sales are in line in the third quarter of 2019.

ACOR : 1.52 (-3.80%)
AVEO : 0.62 (unch)
ALKS : 20.12 (+0.85%)
ZTS : 119.56 (-0.64%)
Horizon Therapeutics' (HZNP) Q3 Earnings Beat Estimates

Horizon Therapeutics (HZNP) beats earnings and sales estimates in the third quarter of 2019.

ACOR : 1.52 (-3.80%)
HZNP : 31.27 (+2.52%)
AVEO : 0.62 (unch)
ALKS : 20.12 (+0.85%)
Esperion (ESPR) Reports Wider-Than-Expected Loss in Q3

Esperion Therapeutics (ESPR) reports mixed third-quarter results.

MRK : 85.27 (+0.73%)
ACOR : 1.52 (-3.80%)
VRTX : 215.07 (+0.03%)
ESPR : 44.76 (-1.95%)
Geron (GERN) Q3 Earnings Beat Estimates, Stock Gains 4.1%

Geron (GERN) reports encouraging third-quarter 2019 results. Operating expenses increase on a year-over-year basis.

JNJ : 135.94 (+0.83%)
ACOR : 1.52 (-3.80%)
GERN : 1.36 (+4.21%)
VRTX : 215.07 (+0.03%)
Perrigo (PRGO) Beats on Q3 Earnings, Tightens '19 EPS View

Perrigo (PRGO) reports mixed third-quarter 2019 results. The Rx segment continues to witness recovery. Stock down.

PRGO : 48.69 (-0.06%)
ACOR : 1.52 (-3.80%)
VRTX : 215.07 (+0.03%)
PETQ : 23.72 (+0.25%)
Intercept (ICPT) Earnings and Sales Miss Estimates in Q3

Intercept (ICPT) reports a wider-than-expected loss and misses on sales in the third quarter of 2019.

ACOR : 1.52 (-3.80%)
ICPT : 86.59 (+1.22%)
AVEO : 0.62 (unch)
ASLN : 0.42 (+1.78%)
Acorda (ACOR) Q3 Earnings and Revenues Surpass Estimates

Acorda (ACOR) posts narrower-than-expected loss with revenues also topping estimates in the third quarter. Inbrija is also off to a promising start with sales rising sequentially.

ACOR : 1.52 (-3.80%)
PRQR : 7.69 (+15.47%)
ANIK : 58.50 (-2.71%)
MYL : 17.24 (-0.17%)
Agenus (AGEN) Q3 Earnings Beat Estimates, Revenues Up Y/Y

Agenus (AGEN) posts narrower-than-expected loss and beats sales estimates in the third quarter of 2019.

GSK : 43.92 (-1.30%)
ACOR : 1.52 (-3.80%)
AGEN : 4.36 (unch)
GILD : 64.88 (-0.18%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Trade ACOR with:

Business Summary

Acorda Therapeutics, Inc. is a biotechnology company developing and commercializing neurology therapies for Parkinson's disease, migraine and multiple sclerosis. Acorda has a pipeline of novel neurological therapies addressing a range of disorders, including Parkinson's disease and multiple sclerosis....

See More

Key Turning Points

2nd Resistance Point 1.63
1st Resistance Point 1.58
Last Price 1.52
1st Support Level 1.48
2nd Support Level 1.43

See More

52-Week High 21.13
Fibonacci 61.8% 13.63
Fibonacci 50% 11.31
Fibonacci 38.2% 8.99
Last Price 1.52
52-Week Low 1.49

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar